DEA Rescheduling Controversy: The Battle Over Cannabis Classification

Executive Summary

The Drug Enforcement Administration's proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act has ignited the most significant regulatory controversy in federal drug policy since the passage of the CSA in 1970. Former DEA administrators, Congressional oversight committees, and industry stakeholders have raised fundamental questions about whether the agency followed its own procedural requirements during the rescheduling review process initiated by the Department of Health and Human Services in August 2023. The controversy centers on allegations that DEA bypassed traditional scientific review protocols, expedited the Notice of Proposed Rulemaking without adequate Administrative Law Judge oversight, and potentially allowed financial considerations from state-legal cannabis markets to influence what should be a purely scientific determination under 21 U.S.C. § 811. With over $30 billion in annual state-legal cannabis sales at stake and 38 states operating medical programs, the procedural integrity of this rescheduling decision carries implications far beyond cannabis policy, potentially setting precedents for how federal agencies handle politically charged scientific determinations. The controversy has exposed deep divisions within federal law enforcement, the scientific community, and between state and federal regulatory frameworks.

Why This Matters

The DEA rescheduling controversy affects every participant in the $30 billion state-legal cannabis industry, 128 million Americans living in adult-use states, and the fundamental relationship between federal drug scheduling and scientific evidence. For the estimated 55 million Americans who use cannabis annually, rescheduling to Schedule III would not legalize possession under federal law but would remove certain research barriers and potentially ease banking restrictions. For the 15,000+ state-licensed cannabis businesses operating across 38 medical and 24 adult-use states, the change would eliminate the punitive effects of Internal Revenue Code Section 280E, which currently prohibits normal business expense deductions for Schedule I and II substances. Industry analysts estimate 280E costs cannabis operators between $3 billion and $5 billion annually in excess federal tax liability. The controversy matters equally for what it reveals about administrative procedure. If DEA did bypass normal review protocols—as alleged by former Administrator Robert Bonner and former Deputy Administrator John Lawn in public statements—it would represent a troubling precedent for how politically sensitive scientific determinations are handled. The Administrative Procedure Act requires agencies to follow consistent processes, and deviations raise questions about whether political pressure from state governments, industry lobbying, or White House directives influenced what should be an objective scientific review. For patients, the stakes are concrete. Approximately 6.4 million Americans hold state-issued medical cannabis cards. Rescheduling could expand research into cannabis-derived pharmaceuticals, potentially leading to FDA-approved medications with standardized dosing and insurance coverage. However, the controversy has delayed implementation, leaving patients in regulatory limbo where state-legal access conflicts with federal prohibition.

Background and History: The Path to Rescheduling

Cannabis has occupied Schedule I of the Controlled Substances Act since the law's enactment on October 27, 1970, classified alongside heroin and LSD as having "no currently accepted medical use" and "high potential for abuse."

The Controlled Substances Act Framework (1970)

The CSA established five schedules of controlled substances, with placement determined by three factors: abuse potential, scientific evidence of medical use, and safety profile. Schedule I represents substances deemed to have the highest abuse potential, no accepted medical use, and lack of accepted safety for use under medical supervision. The statute at 21 U.S.C. § 811 grants the Attorney General (who delegated authority to DEA) power to reschedule substances, but only after receiving a scientific and medical evaluation from the Secretary of Health and Human Services. When Congress passed the CSA, cannabis was included in Schedule I based on recommendations from the Bureau of Narcotics and Dangerous Drugs, despite the ongoing work of the National Commission on Marihuana and Drug Abuse (the Shafer Commission), which would recommend decriminalization in 1972. President Richard Nixon rejected the Shafer Commission findings, and cannabis remained in Schedule I.

Early Rescheduling Petitions (1972-2001)

The first formal petition to reschedule cannabis was filed in 1972 by the National Organization for the Reform of Marijuana Laws. After 16 years of administrative proceedings, DEA Administrative Law Judge Francis Young issued a landmark 1988 ruling stating that cannabis should be moved to Schedule II, finding that "marijuana, in its natural form, is one of the safest therapeutically active substances known to man." DEA Administrator John Lawn rejected Judge Young's recommendation in 1989, a decision upheld by the D.C. Circuit Court of Appeals. Between 1995 and 2001, medical cannabis advocate Jon Gettman filed multiple petitions citing new research on cannabinoid receptors and the endocannabinoid system discovered in the 1990s. DEA denied these petitions in 2001, maintaining that smoked botanical cannabis could not meet FDA standards for an approved medication.

State-Level Medical Programs Create Tension (1996-2012)

California voters approved Proposition 215 in November 1996, establishing the nation's first comprehensive medical cannabis program. By 2012, 18 states had enacted medical programs, creating a growing conflict between state law and federal Schedule I classification. The Obama Administration issued the Cole Memorandum in August 2013, deprioritizing federal enforcement in states with robust regulatory frameworks, but this was a prosecutorial policy, not a change in cannabis's legal status. Colorado and Washington voters approved adult-use legalization in November 2012, with sales beginning in 2014. This created an even starker conflict: states were licensing and taxing commercial production and sale of a substance the federal government classified as having no medical value and high abuse potential.

The 2020 Petition and HHS Review

In October 2020, during the final months of the Trump Administration, several medical cannabis organizations filed a new rescheduling petition. DEA initially took no action, but the Biden Administration's appointment of cannabis reform advocates to key positions changed the political landscape. In October 2022, President Biden issued a statement directing HHS Secretary Xavier Becerra and Attorney General Merrick Garland to "review expeditiously how marijuana is scheduled under federal law." This marked the first time a sitting president had formally requested a scheduling review.

HHS Recommendation (August 2023)

On August 29, 2023, HHS delivered its scientific and medical evaluation to DEA, recommending that cannabis be rescheduled to Schedule III. The HHS recommendation, based on an eight-factor analysis required by 21 U.S.C. § 811(c), concluded that cannabis has a lower abuse potential than Schedule I or II substances, has currently accepted medical use in treatment in the United States, and presents a moderate to low risk of physical dependence. The HHS finding that cannabis has "currently accepted medical use" represented a historic reversal. The agency cited the existence of 38 state medical programs serving millions of patients, FDA approval of cannabis-derived drugs including Epidiolex (cannabidiol), and a growing body of clinical research on therapeutic applications.

DEA's Notice of Proposed Rulemaking (May 2024)

On May 16, 2024, DEA published a Notice of Proposed Rulemaking in the Federal Register, proposing to move cannabis from Schedule I to Schedule III. The NPRM opened a 60-day public comment period, which was later extended to 90 days due to overwhelming response. DEA received over 43,000 public comments, the most in agency history for a scheduling action. The NPRM stated that DEA was "bound by" the HHS scientific and medical evaluation on factors related to medical use and abuse potential, but retained independent authority to consider law enforcement and treaty obligations under the Single Convention on Narcotic Drugs of 1961.

The Procedural Controversy Emerges

Former DEA administrators and agency veterans began publicly questioning the rescheduling process in late 2024, alleging that DEA had deviated from established protocols in ways that compromised the scientific integrity of the review.

Allegations of Bypassed ALJ Review

In testimony before the House Oversight Committee in November 2024, former DEA Administrator Robert Bonner stated that the agency "appears to have bypassed the traditional Administrative Law Judge hearing process that has been standard procedure for contested scheduling decisions since the 1980s." Bonner, who served as DEA Administrator from 1990 to 1993, noted that previous scheduling reviews involving significant scientific disputes—including the 1988 cannabis review—included formal evidentiary hearings before an ALJ. Former Deputy Administrator John Lawn, in a January 2025 interview with Law Enforcement Today, said the process "raises serious questions about whether DEA leadership felt political pressure to reach a predetermined outcome." Lawn oversaw the agency's rejection of ALJ Francis Young's 1988 recommendation to reschedule cannabis. DEA defended its process in a February 2025 statement, noting that ALJ hearings are not statutorily required for all scheduling actions and that the Administrative Procedure Act permits agencies to proceed directly to final rulemaking when an evidentiary hearing would not materially assist the decision. The agency stated that the HHS scientific evaluation, combined with the extensive public comment period, provided adequate basis for a decision.

Questions About the HHS Eight-Factor Analysis

Critics have focused particular attention on how HHS conducted its eight-factor analysis under 21 U.S.C. § 811(c). The statute requires evaluation of: (1) actual or relative potential for abuse; (2) scientific evidence of pharmacological effect; (3) current scientific knowledge; (4) history and current pattern of abuse; (5) scope, duration, and significance of abuse; (6) risk to public health; (7) psychic or physiological dependence liability; and (8) whether the substance is an immediate precursor of a controlled substance. Dr. Bertha Madras, a Harvard Medical School psychobiologist who served on the President's Commission on Combating Drug Addiction during the Trump Administration, published a detailed critique in the Journal of Drug Policy Analysis in March 2025. Madras argued that HHS "selectively cited research supporting lower abuse potential while ignoring substantial evidence of cannabis use disorder, particularly among high-potency concentrate users." She noted that the National Survey on Drug Use and Health found that approximately 16.3% of past-year cannabis users met criteria for cannabis use disorder in 2023, a rate she argued was inconsistent with Schedule III classification. HHS Assistant Secretary for Mental Health and Substance Use Dr. Miriam Delphin-Rittmon defended the analysis in Congressional testimony in April 2025, stating that the evaluation "followed the same rigorous methodology used for all scheduling reviews" and that the finding of moderate-to-low dependence risk was based on comparative analysis with Schedule II substances including cocaine and methamphetamine.

The "Follow the Money" Critique

The June 2026 article in The Joplin Globe, citing former DEA Chief of Operations Derek Maltz, introduced a new dimension to the controversy: the allegation that financial interests from state-legal cannabis markets influenced the federal review process. Maltz stated that "when you have a $30 billion industry and 38 states with established programs, there's enormous pressure on federal agencies to align policy with economic reality rather than scientific evidence." The article noted that cannabis industry trade associations, including the National Cannabis Industry Association and the U.S. Cannabis Council, collectively spent over $4.8 million on federal lobbying in 2023, according to OpenSecrets data. Major multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries have publicly stated that rescheduling is their top federal policy priority due to the tax implications of 280E relief. Smart Approaches to Marijuana, an organization opposing liberalization, released a report in June 2026 documenting meetings between cannabis industry executives and White House Office of National Drug Control Policy staff during the HHS review period. The report alleged that "industry access to the review process was asymmetric, with patient safety advocates and law enforcement receiving less opportunity for input." The White House Office of National Drug Control Policy responded that it "meets with stakeholders across the spectrum on drug policy issues" and that "no meetings with industry representatives involved the substance of the HHS scientific review."

Key Players in the Controversy

Drug Enforcement Administration

DEA Administrator Anne Milgram, appointed by President Biden in June 2021, has faced criticism from both sides of the rescheduling debate. Reform advocates have accused her of delaying implementation of the HHS recommendation, while law enforcement veterans have questioned whether she has maintained the agency's traditional independence from political pressure. Milgram previously served as New Jersey Attorney General and has a background in prosecution rather than drug enforcement operations. The DEA's Diversion Control Division, which oversees controlled substance scheduling, has maintained that the agency is following all statutory requirements. The division's public statements have emphasized that rescheduling to Schedule III would maintain federal controls on cannabis production and distribution, requiring DEA registration for all manufacturers and distributors.

Department of Health and Human Services

HHS Secretary Xavier Becerra directed the Food and Drug Administration to conduct the eight-factor analysis that formed the basis of the August 2023 recommendation. Becerra, former California Attorney General, was a vocal supporter of cannabis reform during his tenure in state office, leading critics to question whether his prior positions influenced the federal review. The FDA's Center for Drug Evaluation and Research conducted the scientific analysis, led by Principal Deputy Commissioner Dr. Namandjé Bumpus. The FDA has maintained that its evaluation was based solely on scientific evidence and that the finding of "currently accepted medical use" was supported by the existence of state medical programs, FDA-approved cannabinoid medications, and published clinical research.

Former DEA Leadership

A group of former DEA administrators and senior officials have emerged as the most vocal critics of the rescheduling process. In addition to Robert Bonner and John Lawn, this group includes: Former Administrator Peter Bensinger (1976-1981), who stated in a May 2025 op-ed that "political considerations appear to have trumped scientific rigor." Former Administrator Asa Hutchinson (2001-2003), now Arkansas Governor, who said the process "raises questions about whether DEA maintained its independence." Former Deputy Administrator Michele Leonhart (2007-2015), who testified before Congress in March 2025 that the expedited timeline "did not allow for adequate review of conflicting scientific evidence." These former officials have emphasized that their opposition is based on procedural concerns rather than opposition to rescheduling per se, though several have also expressed substantive disagreement with the conclusion that cannabis meets Schedule III criteria.

Cannabis Industry and Reform Advocates

The National Cannabis Industry Association, representing over 1,800 state-licensed businesses, has defended the rescheduling process as "long overdue and scientifically justified." NCIA CEO Aaron Smith stated that "the controversy is being manufactured by prohibitionists who refuse to accept the scientific consensus that cannabis has medical value and lower abuse potential than Schedule I or II substances." NORML Political Director Justin Strekal has argued that the real procedural problem is that rescheduling does not go far enough, stating that "cannabis should be completely descheduled and regulated like alcohol, not maintained in the Controlled Substances Act at all." The U.S. Cannabis Council, representing major multi-state operators, has focused its advocacy on the 280E tax implications, with less emphasis on the scientific debate. Industry analysts estimate that Schedule III classification would increase cannabis industry profitability by 20-30% through normal business expense deductions.

Medical and Scientific Community

The medical community has been divided. The American Medical Association has not taken a position on the appropriate schedule for cannabis but has called for expanded research access. The American Academy of Pediatrics has expressed concern about rescheduling without more data on adolescent use impacts. Dr. Nora Volkow, Director of the National Institute on Drug Abuse, has stated that NIDA's research supports the finding that cannabis has lower abuse liability than Schedule I or II substances, while also noting that "high-potency products and concentrate use patterns raise new questions that weren't present in earlier decades." The American Society of Addiction Medicine released a position statement in February 2025 expressing concern that rescheduling "may send a message that cannabis is harmless, when in fact cannabis use disorder is a significant clinical problem, particularly among daily users of high-potency products."

Legal and Regulatory Framework

The legal authority for cannabis rescheduling derives from the Controlled Substances Act at 21 U.S.C. § 811, which establishes a two-agency process requiring scientific evaluation by HHS and scheduling authority by the Attorney General (delegated to DEA).

The Statutory Process

Under 21 U.S.C. § 811(b), the Attorney General may initiate rescheduling proceedings, and must request a scientific and medical evaluation from the Secretary of HHS. The HHS evaluation is binding on DEA with respect to scientific and medical matters, according to the statute's plain language and D.C. Circuit precedent in Americans for Safe Access v. DEA (2013). However, DEA retains independent authority to consider factors beyond the scientific evaluation, including: enforcement data on diversion and trafficking; international treaty obligations under the Single Convention on Narcotic Drugs; and the agency's law enforcement expertise. This division of authority has created tension in the current controversy, with DEA suggesting it may reach a different conclusion than HHS despite being bound by the scientific findings.

Administrative Procedure Act Requirements

The Administrative Procedure Act at 5 U.S.C. § 553 requires agencies to publish proposed rules in the Federal Register, provide opportunity for public comment, and consider all relevant comments before issuing a final rule. DEA has followed these basic requirements, but critics argue the agency has not followed its own precedents for handling contested scheduling decisions. The APA also requires at 5 U.S.C. § 706 that agency actions not be "arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law." Any final DEA decision will be subject to judicial review under this standard, with challenges likely to be filed in the D.C. Circuit Court of Appeals regardless of whether DEA reschedules or maintains Schedule I classification.

International Treaty Obligations

The United States is a signatory to the 1961 Single Convention on Narcotic Drugs, which requires parties to maintain controls on cannabis. However, the treaty allows parties to determine their own scheduling classifications within their domestic legal frameworks. Canada rescheduled cannabis for adult use in 2018 while remaining a party to the Convention, and Uruguay did so in 2013, suggesting that Schedule III classification would not violate treaty obligations. DEA has cited treaty obligations in previous scheduling decisions, but legal scholars including Professor John Walsh of Georgetown University have argued that "the Single Convention provides substantial flexibility and does not mandate Schedule I classification."

The 280E Tax Code Connection

Internal Revenue Code Section 280E prohibits businesses from deducting ordinary business expenses if they traffic in Schedule I or II controlled substances. This provision has been the primary financial burden on state-legal cannabis businesses, forcing them to pay federal income tax on gross revenue rather than net income. Rescheduling to Schedule III would eliminate 280E applicability, but would not legalize cannabis under federal law. State-licensed businesses would still be violating the Controlled Substances Act by manufacturing and distributing cannabis without DEA registration, creating a complex legal situation where businesses could deduct expenses while still engaging in federally prohibited conduct.

State-by-State Landscape

The federal rescheduling controversy unfolds against a backdrop of 38 states with medical cannabis programs and 24 states with adult-use legalization, creating a patchwork of state policies that would be unaffected by federal Schedule III classification.

California

California operates the nation's largest cannabis market, with approximately $5.3 billion in legal sales in 2025. The state's Proposition 64, approved in 2016, legalized adult use for those 21 and older, with possession limits of one ounce of flower and eight grams of concentrate. California has over 1,100 licensed retailers and cultivators. State officials have been vocal supporters of federal rescheduling. Governor Gavin Newsom stated in April 2024 that "federal Schedule I classification is scientifically indefensible and creates unnecessary barriers for California's regulated industry." The California Department of Cannabis Control has emphasized that state regulation would continue unchanged regardless of federal scheduling.

New York

New York legalized adult use through the Marijuana Regulation and Taxation Act in March 2021, with retail sales beginning in December 2022. The state has issued over 300 conditional retail licenses, with possession limits of three ounces of flower. New York's Office of Cannabis Management has focused on social equity licensing, reserving the first retail licenses for individuals with prior cannabis convictions. State officials have argued that federal rescheduling would support these equity goals by reducing the tax burden on small operators.

Florida

Florida operates a medical-only program serving over 800,000 registered patients, the second-largest medical program by patient count after California. Adult-use legalization appeared on the November 2024 ballot but failed to achieve the required 60% supermajority, receiving 57% support. Florida's vertical integration requirement mandates that medical marijuana treatment centers handle cultivation, processing, and retail, creating a market dominated by large operators including Trulieve, which is headquartered in Tallahassee. The state's Republican leadership, including Governor Ron DeSantis, opposed the 2024 adult-use initiative but has supported the medical program.

Texas

Texas maintains one of the most restrictive medical programs, limited to low-THC cannabis (0.5% THC or less) for a narrow list of qualifying conditions. The Texas Compassionate Use Program serves approximately 50,000 registered patients. Texas has not legalized adult use, and state law enforcement continues to prosecute cannabis possession as a criminal offense. However, several Texas cities including Austin, Dallas, and San Antonio have enacted local decriminalization policies. The state's Republican-controlled legislature has repeatedly rejected broader medical access bills.

Ohio

Ohio voters approved adult-use legalization through Issue 2 in November 2023, with sales beginning in August 2024. The state also operates a medical program established in 2016, serving approximately 250,000 registered patients. Adult-use possession limits are 2.5 ounces of flower. Ohio's Division of Cannabis Control regulates both medical and adult-use markets. The state has issued over 400 combined licenses for cultivation, processing, and retail. Ohio's experience illustrates the transition from medical-only to dual-market regulation that many states are navigating.

States Without Legal Access

Twelve states maintain complete prohibition of cannabis, with no medical or adult-use programs: Idaho, Wyoming, Nebraska, Kansas, South Carolina, Tennessee, Alabama, Georgia (medical CBD only), Wisconsin, and Indiana. These states would be unaffected by federal rescheduling, as state law would continue to criminalize possession and use. Law enforcement organizations in prohibition states have generally opposed federal rescheduling, arguing that it would complicate enforcement and send mixed messages about cannabis risks.

Market and Business Implications

Federal rescheduling to Schedule III would fundamentally alter the economics of the cannabis industry by eliminating Section 280E tax penalties, potentially unlocking $3-5 billion in annual tax savings across the sector.

Multi-State Operator Impact

The largest cannabis companies, known as multi-state operators or MSOs, would be the primary beneficiaries of 280E relief. Curaleaf, the largest MSO by revenue with approximately $1.3 billion in 2025 sales, currently pays an effective federal tax rate of approximately 70% due to 280E limitations. The company's executives have stated that Schedule III classification would reduce the effective rate to approximately 25%, increasing net income by an estimated $200-250 million annually. Trulieve, Green Thumb Industries, Cresco Labs, and Verano Holdings—the other top-five MSOs—would see similar impacts. Industry analysts at Cowen & Company estimate that the top 20 MSOs would collectively save approximately $1.8 billion annually in federal taxes under Schedule III. This tax relief could accelerate industry consolidation, as larger operators would have increased capital to acquire smaller competitors. The cannabis industry has been capital-constrained due to federal prohibition on traditional bank lending and securities exchange listings, but 280E relief would improve cash flow and potentially open new financing channels.

Small Operator and Social Equity Concerns

Social equity advocates have expressed concern that 280E relief would disproportionately benefit large MSOs rather than the small and minority-owned businesses that equity programs are designed to support. Kaliko Castille, president of the Minority Cannabis Business Association, stated in testimony before the House Small Business Committee in March 2025 that "rescheduling without addressing banking access and capital formation will widen the gap between well-capitalized MSOs and equity operators." Small operators face challenges beyond 280E, including limited access to capital, high state licensing fees, and competition from established players. While 280E relief would help, many small businesses operate at break-even or losses and would not immediately benefit from tax deductions.

Interstate Commerce and Federal Licensing

Schedule III classification would not automatically enable interstate cannabis commerce, as the Controlled Substances Act prohibits distribution of Schedule III substances without DEA registration. However, legal scholars including Professor Robert Mikos of Vanderbilt Law School have argued that rescheduling could open the door to federal licensing frameworks that would permit interstate transport. The cannabis industry has operated under state-by-state silos, with each state requiring in-state cultivation and processing. Interstate commerce could dramatically reduce costs through economies of scale, with large-scale cultivation in optimal climates (California, Oregon) serving national distribution. However, this would threaten the economic interests of states with less favorable growing conditions that have developed local industries.

Pharmaceutical Development

Rescheduling to Schedule III would reduce regulatory barriers for pharmaceutical companies developing cannabis-derived medications. Currently, research on Schedule I substances requires special DEA licenses and faces significant administrative hurdles. Schedule III classification would align cannabis research with the regulatory framework for medications like ketamine and buprenorphine. Major pharmaceutical companies including Jazz Pharmaceuticals (which acquired GW Pharmaceuticals, maker of Epidiolex) and Pfizer have indicated interest in cannabis-derived drug development. The potential for FDA-approved, insurance-covered cannabis medications represents a parallel track to the state-legal botanical market.

What Experts Say

Expert opinion on the DEA rescheduling controversy divides along disciplinary lines, with medical researchers generally supporting rescheduling, law enforcement veterans expressing procedural concerns, and legal scholars debating the adequacy of the administrative process. Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at the University of California San Diego, stated in a February 2025 interview with JAMA that "the scientific evidence clearly supports the conclusion that cannabis has accepted medical uses and lower abuse potential than Schedule I or II substances." Grant noted that his center has conducted FDA-approved clinical trials on cannabis for chronic pain, PTSD, and other conditions, finding therapeutic benefit with manageable side effects. Dr. Sharon Levy, director of the Adolescent Substance Use and Addiction Program at Boston Children's Hospital, expressed a more cautious view in testimony before the Senate Health Committee in March 2025, stating that "while cannabis may have medical applications for adults, we have significant concerns about adolescent access and the normalization message that rescheduling may send." Levy cited data showing that 30.7% of high school seniors reported past-year cannabis use in 2024, according to the Monitoring the Future survey. Professor Alex Kreit of Northern Kentucky University Chase College of Law, an expert on drug scheduling law, argued in a law review article published in April 2025 that DEA's process "appears consistent with the Administrative Procedure Act, even if it deviates from the agency's own informal precedents." Kreit noted that the APA does not require evidentiary hearings for all rulemakings and that DEA has discretion to streamline procedures when the scientific record is clear. Kevin Sabet, president of Smart Approaches to Marijuana and former senior drug policy advisor in the Obama Administration, has been the most prominent critic of rescheduling. In a June 2025 statement, Sabet said "the process has been driven by industry lobbying and state revenue interests, not by rigorous scientific review." He pointed to data from the National Survey on Drug Use and Health showing that cannabis use disorder rates have increased as state legalization has expanded. Morgan Fox, political director of NORML, countered that "the real controversy is that cannabis was ever placed in Schedule I in the first place, given that the decision was political rather than scientific from the beginning." Fox argued that the current process, while imperfect, represents "the first time the federal government has seriously engaged with the scientific evidence on cannabis."

What's Next: Timeline and Scenarios

DEA faces a decision point in late 2026 or early 2027, with three possible outcomes: finalize rescheduling to Schedule III as proposed, maintain Schedule I classification, or pursue an alternative classification such as Schedule II or IV.

Immediate Calendar

The public comment period on the May 2024 NPRM closed in August 2024. DEA is required to review all 43,000+ comments and prepare responses to significant issues raised. The agency has provided no firm timeline for a final rule, but administrative law experts estimate the review process will take 12-18 months from the close of comments. Congressional oversight hearings are scheduled for July and September 2026 in both the House Energy and Commerce Committee and the Senate Judiciary Committee. These hearings will likely feature testimony from DEA Administrator Milgram, HHS officials, and outside experts on both sides of the controversy.

Scenario 1: Finalize Schedule III Rescheduling

If DEA finalizes the proposed Schedule III classification, the rule would take effect 30 days after publication in the Federal Register. Cannabis businesses would immediately become eligible for normal business expense deductions under the tax code, though the IRS would need to issue guidance on implementation. However, Schedule III classification would not legalize cannabis under federal law. State-licensed businesses would still be violating 21 U.S.C. § 841 (manufacture and distribution) and would technically require DEA registration as handlers of a Schedule III controlled substance. DEA has not indicated how it would handle this conflict, though most observers expect the agency would continue its current policy of non-enforcement in states with robust regulatory frameworks. Legal challenges would be certain. Smart Approaches to Marijuana and other prohibition advocates would likely file suit in the D.C. Circuit arguing that the decision was arbitrary and capricious. Cannabis reform advocates might also challenge the decision as insufficiently protective of state-legal programs.

Scenario 2: Maintain Schedule I Classification

If DEA rejects the HHS recommendation and maintains Schedule I classification, the agency would need to articulate a clear rationale for disagreeing with HHS's scientific findings. While DEA has independent authority on law enforcement factors, the statute makes HHS's scientific evaluation binding on medical and scientific questions. This scenario would likely trigger immediate litigation from cannabis industry groups and reform advocates, arguing that DEA exceeded its statutory authority by rejecting HHS's binding scientific determination. The D.C. Circuit would review the decision under the arbitrary and capricious standard. Politically, maintaining Schedule I would create significant tension with the 38 states operating medical programs and could become an issue in the 2028 presidential election, particularly if younger voters view it as out of step with scientific consensus.

Scenario 3: Alternative Classification

Some observers have speculated that DEA might propose an alternative classification, such as Schedule II (high abuse potential but accepted medical use) or Schedule IV (lower abuse potential than Schedule III). However, this would require reopening the rulemaking process with a new NPRM, significantly delaying any final decision. Schedule II classification would maintain 280E applicability, eliminating the primary industry interest in rescheduling. Schedule IV classification would be difficult to justify given that it includes substances like Xanax and Ambien, which have different risk profiles than cannabis.

Congressional Action

Congress could preempt DEA's decision through legislation. The Cannabis Administration and Opportunity Act, introduced by Senate Majority Leader Chuck Schumer in multiple sessions, would deschedule cannabis entirely and create a federal regulatory framework similar to alcohol. However, the bill has not advanced due to Republican opposition in the House. The SAFER Banking Act, which would provide legal clarity for financial institutions serving cannabis businesses, has passed the House multiple times but stalled in the Senate. Some observers believe a compromise version could pass in 2027, potentially rendering the scheduling question less economically significant.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — Full text of the federal statute governing drug scheduling: https://www.deadiversion.usdoj.gov/21cfr/21usc/index.html
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling, 89 Fed. Reg. 44594 (May 16, 2024) — Official NPRM proposing Schedule III classification: https://www.federalregister.gov/documents/2024/05/16
• HHS Recommendation to Reschedule Marijuana (August 2023) — Scientific and medical evaluation supporting Schedule III: https://www.hhs.gov/about/news/2023/08/29
• Administrative Procedure Act, 5 U.S.C. § 551 et seq. — Federal law governing agency rulemaking procedures: https://www.law.cornell.edu/uscode/text/5/part-I/chapter-5